Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Reviva Pharmaceuticals reported a net loss of $7.9 million for the nine months ended September 30, 2026, a significant reduction from the $16.5 million loss in the prior year period. The company strengthened its liquidity through public and ATM offerings, ending the quarter with $17.5 million in cash and cash equivalents.
Bio Essence Corp. reported a net income of $324,992 for the nine months ended September 30, 2026, a significant improvement from a net loss of $132,890 in the prior year period. Despite this profitability, the company maintains a working capital deficit of $1,374,178 and an accumulated deficit of over $9.2 million, leading management to express substantial doubt about its ability to continue as a going concern.
Reviva Pharmaceuticals reported a net loss of $2.3 million for the third quarter of 2026, an improvement from a $4.0 million loss in the prior year period. The company is awaiting FDA feedback in Q4 2026 regarding a new formulation of brilaroxazine for its Phase 3 RECOVER-2 trial in schizophrenia. Reviva also noted it has filed a new composition of matter patent application that could extend protection for brilaroxazine through 2046.
Term
Q3 2026
“Our near-term focus is obtaining Food and Drug Administration (FDA) feedback on the proposed use of a new formulation of brilaroxazine and preparing for the next stages of clinical development while managing our capital resources carefully.”
Laxminarayan Bhat, Founder, President, and CEO of Reviva
“We remain focused on disciplined execution as we advance brilaroxazine as a potentially differentiated treatment option for patients with schizophrenia.”
Laxminarayan Bhat, Founder, President, and CEO of Reviva
SoundHound AI, Inc. filed an amendment to its previous 8-K to provide required financial statements and pro forma information following its completed merger with LivePerson, Inc. The filing includes audited and unaudited financial data for LivePerson and combined pro forma financials to help investors assess the impact of the acquisition.
Aardvark Therapeutics reported a net loss of $19.2 million for the third quarter of 2026, driven by increased research and development costs. The company's cash position remains at $60.3 million as it continues to transition from its 2025 initial public offering to fund its clinical-stage metabolic disease pipeline.
Almonty Industries reported a 382% year-over-year revenue increase to $41.9 million for Q3 2026, driven by a surge in tungsten prices and the commencement of commercial operations at the Sangdong Mine. Net income reached $50.2 million, supported by significant non-cash gains on derivative revaluations, while the company ended the quarter with a strong cash position of $1.15 billion.
Buda Juice, Inc. reported net sales of $13.22 million for the nine months ended September 30, 2026, a significant increase from $9.71 million in the prior year. Following its January 2026 IPO and conversion to a C corporation, the company ended the period with $19.28 million in cash and cash equivalents, up from $1.84 million at the start of the year.
TEN Holdings, Inc. held its 2026 Annual Meeting of Stockholders on November 12, 2026. Shareholders elected four directors to the board and ratified the appointment of AssentSure PAC as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
REALLOYS INC. reported a significant increase in net revenues to $1.92 million for the nine months ended September 30, 2026, compared to $0.63 million in the prior year, though it incurred a substantial net loss of $174.1 million driven by high general and administrative expenses and stock-based compensation. The company completed a reverse recapitalization in February 2026 and significantly strengthened its cash position to $116.2 million following various equity issuances.
SKYX Platforms reported record third-quarter revenue of $25.7 million, representing 7.4% year-over-year growth and its 11th consecutive quarter of growth. The company highlighted its recent merger with Deako, which expanded its builder channel pipeline to approximately 4 million units. Management noted a strong cash position of $21 million and believes it has sufficient capital to reach cash-flow positive status.
Nakamoto Inc. reported Q3 2026 net income of $85.5 million, driven primarily by a $110.4 million gain in the fair value of its digital asset holdings. The company reported total operating revenue of $(1.9) million due to derivative losses and highlighted the extension of its Kraken loan facility maturity to December 2027.
Term
Q3 2026
“We spent the third quarter building. We launched Bitcoin Magazine TV to add year-round sponsorship revenue, took UTXO into structured credit, and held Bitcoin Asia in Hong Kong. We also announced Intelligence 2027, our first event built around AI. i27 takes our events business behind The Bitcoin Conference into the intersection between AI, investment, enterprise adoption and policy.”
David Bailey, Chairman and Chief Executive Officer of Nakamoto
“Markets move in cycles, and we are building Nakamoto to perform through all of them, by extending our debt maturities and building operating businesses that earn revenue beyond our Bitcoin holdings. We are confident that these initiatives and our selective approach to deploying capital will help us drive sustainable earnings and long-term shareholder value.”
David Bailey, Chairman and Chief Executive Officer of Nakamoto
Enovix Corp reported revenue of $11.0 million for the fiscal quarter ended October 4, 2026, up from $8.0 million in the prior year period. The company reduced its quarterly loss from operations to $39.3 million compared to $47.0 million in 2025, while maintaining a strong liquidity position with $405.5 million in cash and short-term investments.
HawkEye 360, Inc. significantly strengthened its balance sheet in 2026, with cash and cash equivalents increasing to $494.9 million from $92.7 million at year-end 2025. The company transitioned from a stockholders' deficit to a total stockholders' equity of $805.3 million, primarily driven by the conversion of mezzanine equity and an increase in additional paid-in capital.
Gemini Space Station, Inc. reported a total asset decrease from $1.80 billion at year-end 2025 to $1.58 billion as of September 30, 2026, driven by declines in cash and crypto assets held. The company's accumulated deficit widened to $2.32 billion, reflecting ongoing net losses during the period.
Cartesian Growth Corporation IV is a blank check company that completed its IPO in June 2026, raising $275 million. As of September 30, 2026, the company reported a net income of $2.3 million for the quarter, primarily driven by interest earned on investments held in the Trust Account, and is currently seeking a target for a business combination.
GigCapital9 Corp. is a shell company that completed its initial public offering in January 2026, raising $253 million. For the nine months ended September 30, 2026, the company reported net income of $5.1 million, primarily driven by $6.1 million in interest and dividend income from marketable securities held in its Trust Account.
Nova Minerals Corp reported a net loss of $12.0 million for the quarter ended September 30, 2026, compared to a $6.4 million loss in the prior year, driven primarily by increased exploration and evaluation expenses. The company is transitioning its focus toward developing a pilot-scale antimony processing facility in Alaska, supported by a $43.4 million award from the U.S. Department of War.
Silence Therapeutics reported a net loss of $39.7 million for the nine months ended September 30, 2026, a significant improvement from the $76.8 million loss in the prior year period. The company strengthened its balance sheet through a major share issuance in the third quarter, bringing cash and cash equivalents to $247.7 million, which management believes will fund operations until at least 2028.
York Space Systems Inc. reported a significant increase in total current assets to $579.2 million as of September 30, 2026, driven by growth in cash and contract assets. The company is actively executing an M&A strategy, highlighting recent acquisitions of Orbion Space Technologies, Solestial Space Technology, and All.Space Holdings.
Ameresco $125M Debt Financing with Nuveen Energy Infrastructure Credit
Ameresco's indirect subsidiary, Ameresco Euro Holdco Limited, entered into a $125 million senior secured credit agreement with Nuveen Energy Infrastructure Credit, with an option to expand by an additional $100 million. The facility matures in November 2031 and is designed to fund solar, battery storage, and energy efficiency projects across the UK and Europe. The financing is structured with limited recourse to the parent company and does not impact its senior secured corporate leverage ratios.
Bolt Biotherapeutics reported a net loss of $19.5 million for the nine months ended September 30, 2026, a significant reduction from the $26.7 million loss in the prior year period. The company recently acquired Prana Therapies, Inc. to pivot its focus toward the INSPIRE platform for multispecific antibodies while completing Phase 1/2 trials for BDC-4182.
Moodys Debt Financing Update with U.S. Bank Trust Company, National Association
Moody’s Corporation closed a public offering of €500 million aggregate principal amount of 4.125% Senior Notes due 2033. The notes were issued under a Twentieth Supplemental Indenture and the company intends to use the proceeds for general corporate purposes, including the repayment of its 1.75% Senior Notes due 2027.
ImmuCell reported Q3 2026 financial results with revenue growing 46% to $8.0 million and net income of $953,000. The company highlighted broad-based growth across sales territories and announced the termination of its At-The-Market (ATM) offering program due to a strong cash position.
Term
Q3 2026
“ImmuCell had a strong quarter. The expanded commercial team is delivering solid revenue growth as we reach more customers with our value propositions. Increased commercial activity was supported by increased output from the manufacturing team. We are investing in capacity expansion and colostrum sourcing capabilities for future demand, and those efforts are projected to be completed on time and within budget.”
Olivier te Boekhorst, President and CEO
“Today we are reporting net income of $953,000 for the third quarter of 2026, a $1.1 million increase compared to the third quarter of 2025. Revenue grew 46.0% to $8.0 million in the third quarter of 2026 compared to the third quarter of 2025, a comparison aided in part by the absence of distributor restocking headwinds that had adversely affected the third quarter sales in 2025.”
Liftoff Mobile, Inc. filed its 10-Q for the period ending September 30, 2026, following its June 2026 IPO. The company is classified as an emerging growth company and non-accelerated filer, reporting 169,444,265 shares of common stock outstanding as of November 5, 2026.
Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on developing rezpegaldesleukin (NKTR-358) for autoimmune diseases. The company reported a transition to a non-accelerated filer status and continues to incur substantial net losses while relying on collaboration agreements and capital markets for funding.
The Tennessee Valley Authority's 2026 10-K filing outlines its financial and operational structure, including new accounting standards and risk management activities. The document highlights significant environmental and regulatory matters, such as compliance with the 2015 CCR Rule and the Clean Air Act, alongside strategic initiatives like the Enterprise Transformation Program.
NeoVolta Inc. reported a significant revenue decline to $2.79 million for the quarter ended September 30, 2026, compared to $6.65 million in the prior year, resulting in a net loss of $7.73 million. The company significantly increased its cash position through a secured debt facility, ending the period with $25.97 million in cash and cash equivalents.
CV Sciences reported a net loss of $1.5 million for the nine months ended September 30, 2026, compared to a loss of $0.8 million in the prior year period, primarily driven by a decrease in product sales and non-cash losses on debt conversions. Despite the net loss, the company generated positive cash flow from operations of $0.18 million and recorded a $0.5 million gain from a legal settlement during the third quarter.
Karbon Capital Partners Corp. reported net income of $7.25 million for the nine months ended September 30, 2026, primarily driven by $9.42 million in interest earned on marketable securities held in trust. As a shell company, it has not yet generated operating revenue and is currently focused on identifying a target for a business combination.
MariMed Inc. reported revenue of $44.2 million for the third quarter of 2026, a 9% increase year-over-year, though it recorded a net loss of $3.5 million due to high income tax provisions and interest expenses. The company's balance sheet shows $10.4 million in cash and a total of 405,996,010 common shares outstanding as of November 10, 2026.